Centrexion Therapeutics Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Centrexion Therapeutics Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3306
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its synthetic trans capsaicin ultra-pure injection develops a proprietary injectable therapy designed to provide fast acting, long lasting and targeted pain relief. Centrexion Therapeutics products are used to treat morton’s neuroma and knee osteoarthritis. The company’s research and clinical trial develops novel pain therapeutics for various conditions. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.

Centrexion Therapeutics Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 11
Venture Financing 13
Centrexion Therapeutics Raises USD67 Million in Series D Financing 13
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 15
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 16
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 17
Centrexion Therapeutics Raises USD7 Million in Venture Financing 18
Centrexion Raises USD14.7 Million in Venture Financing 19
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 20
Debt Offering 21
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp – Key Competitors 22
Centrexion Therapeutics Corp – Key Employees 23
Centrexion Therapeutics Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Aug 15, 2018: Centrexion Therapeutics names Dan Mendelson as Board Director 25
Jul 30, 2018: Centrexion Therapeutics names Nick Harvey as chief financial officer 26
Jun 26, 2018: Centrexion Therapeutics Names Joseph R. Swedish As Board Director 27
Jun 26, 2017: Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors 28
Product News 29
08/29/2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017 29
06/07/2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology 30
05/10/2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting 31
Product Approvals 32
Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain 32
Clinical Trials 33
Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018 33
Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017 34
Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit 35
Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting 36
Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain 37
May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress 39
Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA 40
Mar 16, 2017: Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 11
Centrexion Therapeutics Raises USD67 Million in Series D Financing 13
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 15
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 16
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 17
Centrexion Therapeutics Raises USD7 Million in Venture Financing 18
Centrexion Raises USD14.7 Million in Venture Financing 19
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 20
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp, Key Competitors 22
Centrexion Therapeutics Corp, Key Employees 23

List of Figures
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Centrexion Therapeutics Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes medicines for the treatment of epilepsy and other neuropsychiatric disorders. The company is evaluating its lead product candidate Ganaxolone, a gamma-aminobutyri …
  • Indago Energy Ltd (INK):石油・ガス:M&Aディール及び事業提携情報
    Summary Indago Energy Ltd (Indago), formerly Pryme Energy Ltd is a provider of specialist oil and gas production chemicals. The company offers acquisition, up-gradation, exploration and production services to onshore oil and natural gas. It holds interests in the Newkirk project located in Kay Count …
  • Allegiance Capital Corporation:企業の戦略・SWOT・財務分析
    Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Allegiance Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Marquard & Bahls AG:企業の戦略・SWOT・財務分析
    Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report Summary Marquard & Bahls AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Daewoong Pharmaceutical Co Ltd (069620):企業の財務・戦略的SWOT分析
    Daewoong Pharmaceutical Co Ltd (069620) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Vertu Motors Plc:企業のM&A・事業提携・投資動向
    Vertu Motors Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vertu Motors Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Medical Prognosis Institute A/S (MPI):企業の財務・戦略的SWOT分析
    Summary Medical Prognosis Institute A/S (MPI) is a precision medicine provider that offers cancer treatment solutions. The company offers drug response prediction platforms that provide tools for rationalized drug development and personalized medicine. It offers lead compound selection, drug rescue …
  • Konka Group Co., Ltd.
    Konka Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Konka Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Virgin Islands Water and Power Authority:企業の戦略的SWOT分析
    Virgin Islands Water and Power Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Buck Institute for Research on Aging-製薬・医療分野:企業M&A・提携分析
    Summary Buck Institute for Research on Aging (Buck Institute) is a healthcare institute that conducts research and offers educational services. The institute concentrates on understanding the connection between aging and chronic disease. It works to understand how normal aging contributes to the dev …
  • Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) t …
  • Martifer SGPS SA (MAR):企業の財務・戦略的SWOT分析
    Martifer SGPS SA (MAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • METRO Retail Stores Group Inc (MRSGI):企業の財務・戦略的SWOT分析
    METRO Retail Stores Group Inc (MRSGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Ambac Financial Group Inc (AMBC):企業の財務・戦略的SWOT分析
    Ambac Financial Group Inc (AMBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • NRG Energy Inc (NRG):企業の財務・戦略的SWOT分析
    NRG Energy Inc (NRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Redbiotec AG-製薬・医療分野:企業M&A・提携分析
    Summary Redbiotec AG (Redbiotec) is a biopharmaceutical company that develops prophylactic vaccines, which target various virus associated diseases. The company produces multi component virus like particles and other protein assemblies through its rePAX coexpression technology. It is developing prod …
  • Metro AG:企業のM&A・事業提携・投資動向
    Metro AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Metro AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Penumbra Inc (PEN):企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cancer Research UK-製薬・医療分野:企業M&A・提携分析
    Summary Cancer Research UK (CRUK) is a research institution which offers clinical research services to treat cancer. The institute offers research services for womb cancer, lung cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children's ca …
  • S. Kumars Nationwide Ltd:企業の戦略・SWOT・財務情報
    S. Kumars Nationwide Ltd - Strategy, SWOT and Corporate Finance Report Summary S. Kumars Nationwide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆